What Solani Therapeutics does

Solani Therapeutics Ltd., founded in 2014 and headquartered in Oulu, Finland, is a privately held veterinary pharmaceutical developer with 1-10 employees. The company combines already-marketed active pharmaceutical ingredients, primarily meloxicam, with novel formulations and delivery methods to produce extended-release pain management products for companion and production animals. Its core technology is a subcutaneously injectable silica-hydrogel depot platform licensed from DelSiTech Ltd since 2015, which enables controlled release of active ingredients over periods ranging from 3-5 days to 30 days depending on the formulation.

The product portfolio comprises five core assets: ST14D, a 30-day subcutaneous meloxicam depot for canine osteoarthritis; ST15C, a 3-5 day meloxicam hydrogel for feline post-operative pain; ST18D, a 3-5 day depot for canine post-operative pain; ST18P, an intramuscular meloxicam depot for piglet castration analgesia; and the BoviBolus delivery cartridge, a cellulose-based oral solid delivery device for cattle. The company holds granted patents for its slow-release meloxicam solution in the European Union (2019), United States (2020), Australia (2022), and New Zealand (2024).

Solani operates an asset-light, partnership-driven business model. It does not sell products directly; instead, it generates revenue through technology and product licensing, co-development deals for early-stage pipeline assets, and milestone payments. Its sole commercialized product, BoviBolus, is licensed to Vetcare Ltd for commercialization in Europe and North America under a 2016 agreement, while the company is actively seeking distribution partners for Rest of World markets (Brazil, Australia, New Zealand) and co-development partners for its ST15C, ST18D, and ST18P pipeline projects.

Name

Solani Therapeutics

Legal name

Solani Therapeutics Ltd.

Website

https://solanitherapeutics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Solani Therapeutics is a Finnish veterinary pharmaceutical developer that combines marketed active ingredients with proprietary silica-hydrogel delivery technology to produce extended-release pain management formulations for companion and production animals, commercializing via licensing and co-development partnerships.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

akta.pro secondary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

Keywords

• Veterinary pharmaceuticals
• Extended-release formulations
• Drug delivery technology
• Animal pain management
• Silica-hydrogel depots

Headquarters

HQ city

Oulu

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Product Licensing: Licensing of proprietary formulations and delivery technologies to pharmaceutical partners for commercialization. Includes technology license agreements (e.g., DelSiTech silica-hydrogel technology) and product-specific licenses (e.g., BoviBolus delivery cartridge to Vetcare).
2. Co-development Deals: Early-stage co-development partnerships where Solani contributes formulation expertise and receives development funding or milestone payments. The company is actively seeking co-development deals for ST15C, ST18D, and ST18P projects.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Solani Therapeutics develops novel extended-release veterinary pain management products for companion and production animals by combining already-marketed active pharmaceutical ingredients (notably meloxicam) with proprietary silica-hydrogel depot formulations and a cellulose-based oral delivery cartridge. Its portfolio includes injectable meloxicam depots providing 3–30 days of sustained pain relief for dogs, cats, and piglets, plus an oral delivery cartridge (BoviBolus) for cattle that is commercialized by partner Vetcare.

Product overview

Solani Therapeutics develops extended-release veterinary pain management solutions combining already marketed active pharmaceutical ingredients with novel formulations and delivery methods. The company offers a portfolio of products including: ST15C (meloxicam hydrogel for cats with 3-5 day release), ST18D (meloxicam depot for post-operative pain in dogs), ST18P (meloxicam depot for piglet castration analgesia), ST14D (meloxicam depot for dogs with 30-day release for osteoarthritis), and a delivery cartridge for cattle (BoviBolus). The products utilize silica-hydrogel drug delivery technology licensed from DelSiTech and focus on easing drug administration to ensure successful therapy outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

• ST14D (Canine Osteoarthritis Meloxicam Hydrogel Depot) Controlled-release subcutaneously injectable meloxicam hydrogel depot delivering 30 days of sustained pain relief from a single injection for dogs with osteoarthritis, eliminating the need for daily oral meloxicam administration. Dosing for dogs of different weights is achieved by adjusting injection volume.
• ST15C (Feline Post-Operative Meloxicam Hydrogel) Subcutaneously injectable meloxicam hydrogel for cats with a 3 to 5 day release time, administered by a veterinarian before or after an operation as a replacement for at-home oral suspension treatments.
• ST18D (Canine Post-Operative Meloxicam Silica-Hydrogel Depot) Injectable (subcutaneous) meloxicam silica-hydrogel depot for post-operative pain management in dogs, providing slow-release pain relief for 3 to 5 days after a single administration.
• ST18P (Piglet Castration Analgesia Meloxicam Depot) Intramuscularly injectable meloxicam silica-hydrogel depot intended to manage inflammation and pain in piglets for a longer period than marketed drug products for castration analgesia.
• BoviBolus Delivery Cartridge (Cellulose-Based Oral Delivery Cartridge for Cattle) A cellulose-based cartridge with a cap for oral solid delivery to cattle, administered with commonly used bolus guns and compatible with oral solids up to 100 millilitres in volume, developed in collaboration with Vetcare Ltd.

Quantifiable outcome

• 35% of dogs affected by osteoarthritis
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Vetcare LtdcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2016License agreement signed in 2016 for delivery cartridge BoviBolus. Vetcare commercializes the product in Europe and North America, with Solani seeking distribution partners in ROW (Brazil, Australia, New Zealand).
• DelSiTech LtdcoreTechnology or Integration · 1 January 2015Technology license agreement signed in 2015 allowing commercial exploitation of DelSiTech's silica-hydrogel technology in meloxicam-based veterinary drugs. This technology forms the foundation of Solani's extended-release formulations including ST14D.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company with strong focus on companion animal pain management and endocrinology. Highly comparable to Solani given its portfolio of novel formulations in the same therapeutic area and similar licensing/partnership-driven growth model prior to its acquisition by Zoetis.
• Vetoquinol: Independent veterinary pharmaceutical company focused on companion and production animals with a meaningful pain/inflammation portfolio. Comparable to Solani as a mid-sized specialty player developing differentiated formulations for animal pain management.
• Virbac: Dedicated animal health company offering pharmaceuticals, vaccines and diagnostics across companion and production animals. Comparable to Solani in its pursuit of specialty veterinary therapeutics, including pain and anti-inflammatory categories.
• Norbrook Laboratories: Privately held veterinary pharmaceutical manufacturer with a strong focus on production animal therapeutics and generic veterinary drugs. Comparable to Solani given its focus on production animal health (cattle, pigs) and its independent, non-public ownership status.
• Phibro Animal Health: Animal health and nutrition company with a meaningful livestock/production animal pharmaceutical portfolio. Comparable to Solani particularly for the ST18P and BoviBolus production-animal products targeting cattle and pig producers.
• Ceva Santé Animale: Global veterinary pharmaceutical company focused on companion and production animal health, with active development of novel formulations and delivery systems. Comparable to Solani given its specialty positioning and investment in differentiated delivery technologies.
• Chanelle Pharma: Veterinary pharmaceutical manufacturer specializing in generic and innovative animal health products across companion and livestock species. Comparable to Solani as a smaller, privately held vet pharma company developing differentiated formulations.
• Parnell Pharmaceuticals: Veterinary pharmaceutical company with a portfolio spanning companion animal pharmaceuticals and production animal reproductive technologies. Comparable to Solani given its specialty veterinary focus and product licensing/partnership model.

Broad incumbents

• Zoetis: World's largest animal health company with a broad portfolio across species and therapeutic categories including pain management. Relevant incumbent peer — Solani would compete against Zoetis in companion animal NSAIDs, and could in the future be an acquisition or licensing partner for the broader portfolio.
• Elanco Animal Health: Major global animal health company with strong companion animal and livestock pharmaceutical portfolios. Comparable as a broad incumbent in the same therapeutic areas Solani targets, with significantly larger R&D, regulatory and commercial resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/solani-therapeutics-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solani Therapeutics